Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.44 |
| ▸ | HTR1A | P08908 | 5/20 | 0.42 |
| ▸ | DRD2 | P14416 | 5/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.42 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.41 |
| ▸ | CDK9 | P50750 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 2/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL303043 | 0.85 | KDM4E (0.50) | DRD2NPFFR1NPFFR2KDM4EMEN1 | |
| SCHEMBL29995938 | 0.79 | NPFFR1 (0.49) | DRD2NPFFR1NPFFR2KMT2ANAMPT | |
| SCHEMBL4405362 | 0.79 | HTR6 (0.38) | HTR6CCNT1CDK9NAMPT | |
| SCHEMBL27659007 | 0.76 | OPRM1 (0.48) | HTR6HTR1ADRD2HTR2AHTT | |
| SCHEMBL973546 | 0.76 | OPRM1 (0.52) | HTR6HTR1ADRD2HTR2AHTT | |
| SCHEMBL4405361 | 0.76 | HTR6 (0.37) | HTR6CCNT1CDK9NAMPTEGLN1 | |
| SCHEMBL2034984 | 0.74 | PTGDR2 (0.47) | HTR6MEN1KMT2ANAMPT | |
| SCHEMBL7041028 | 0.73 | NAMPT (0.55) | HTR1ADRD2NPFFR1NPFFR2OPRM1 | |
| SCHEMBL14087069 | 0.73 | DRD2 (0.47) | DRD2NPFFR1NPFFR2KDM4EMEN1 | |
| SCHEMBL6043002 | 0.72 | DRD2 (0.59) | HTR6HTR1ADRD2HTR2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2483243-B1 | SYNTHESIS OF (4-FLUORO-3-PIPERIDIN-4-YL-BENZYL)-CARBAMIC ACID TERT-BUTYL ESTER AND INTERMEDIATES THEREOF | SANOFI AVENTIS US LLC (US) | 2015-03-18 | — | — | EP | disclosed |
| US-8633321-B2 | Synthesis of (4-fluoro-3-piperidin-4-yl-benzyl)-carbamic acid tert-butyl ester and intermediates thereof | SANOFI-AVENTIS U.S. LLC (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633321-B2 | Synthesis of (4-fluoro-3-piperidin-4-yl-benzyl)-carbamic acid tert-butyl ester and intermediates thereof | SANOFI-AVENTIS U.S. LLC (US) | 2014-01-21 | — | — | US | disclosed |
| US-20130225825-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-08-29 | — | — | US | disclosed |
| US-20120184745-A1 | SYNTHESIS OF (4-FLUORO-3-PIPERIDIN-4-YL-BENZYL)-CARBAMIC ACID TERT-BUTYL ESTER AND INTERMEDIATES THEREOF | SANOFI-AVENTIS U.S. LLC (US) | 2012-07-19 | — | — | US | disclosed |
| US-20110015400-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-01-20 | — | — | US | disclosed |
| EP-1723140-B1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | AVENTIS PHARMA INC (US) | 2009-11-04 | — | — | EP | disclosed |
| US-20070197597-A1 | Process for the preparation of tryptase inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
| US-20070142435-A1 | [4-(5-Aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070142435-A1 | [4-(5-Aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-21 | — | — | US | disclosed |
| EP-1737848-A1 | [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-(4-BROMO-3-METHYL-5-PROPOXY-THIOPHEN-2-YL)-METHANONE HYDROCHLORIDE AS AN INHIBITOR OF MAST CELL TRYPTASE | Aventis Pharmaceuticals Inc. (US) | 2007-01-03 | — | — | EP | disclosed |
| EP-1723140-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005097780-A1 | [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-(4-BROMO-3-METHYL-5-PROPOXY-THIOPHEN-2-YL)-METHANONE HYDROCHLORIDE AS AN INHIBITOR OF MAST CELL TRYPTASE | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005097780-A1 | [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-(4-BROMO-3-METHYL-5-PROPOXY-THIOPHEN-2-YL)-METHANONE HYDROCHLORIDE AS AN INHIBITOR OF MAST CELL TRYPTASE | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005095385-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225825-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | CMA1, TPSAB1, TPSB2 | HTR6 646/4885HTR1A 295/4885DRD2 3103/4885 |
| US-20070142435-A1 | [4-(5-Aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase | CMA1, TPSAB1, TPSB2 | HTR6 63/4885HTR1A 52/4885DRD2 2382/4885 |
| US-20110015400-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | CMA1, TPSAB1, TPSB2 | HTR6 646/4885HTR1A 295/4885DRD2 3103/4885 |
| US-20120184745-A1 | SYNTHESIS OF (4-FLUORO-3-PIPERIDIN-4-YL-BENZYL)-CARBAMIC ACID TERT-BUTYL ESTER AND INTERMEDIATES THEREOF | TBC1D5, TBC1D15, TERT | HTR6 1837/4885HTR1A 2693/4885DRD2 2750/4885 |
| US-20070197597-A1 | Process for the preparation of tryptase inhibitors | CMA1, TPSAB1, TPSB2 | HTR6 646/4885HTR1A 295/4885DRD2 3103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.